---
title: "Neurizon Therapeutics Announces Half-Year Update Webinar"
date: "2025-02-11 11:33:03"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart PortfolioThe latest update is out from..."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1306769920-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

The latest update is out from Pharmaust Limited ( [(AU:NUZ)](https://www.tipranks.com/stocks/au:nuz) ).

Neurizon Therapeutics Limited announced it will host a webinar titled ‘Half-Year Update: Key Developments & Future Outlook’ to provide insights into its recent developments, ongoing progress, and strategic priorities. The event, hosted by CEO Dr. Michael Thurn, is scheduled for February 17, 2025, and aims to engage stakeholders by offering a platform for questions and interaction. This initiative underscores Neurizon’s commitment to transparency and stakeholder engagement, potentially impacting its industry positioning and reinforcing its strategic focus.

**More about Pharmaust Limited**

Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is advancing its lead drug candidate, NUZ-001, for the treatment of ALS, the most common form of motor neurone disease. Neurizon aims to accelerate access to effective ALS treatments and explore broader applications of NUZ-001, leveraging international collaborations and rigorous clinical programs.

**YTD Price Performance:** -16.48%

**Average Trading Volume:** 5,132

**Technical Sentiment Consensus Rating:** Hold

**Current Market Cap:** €41.84M

See more insights into NUZ stock on [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/au:nuz/stock-analysis).

Trending Articles:
------------------

* [‘Don’t Wait for the Dominoes to Fall,’ Says Top Investor About Palantir Stock](https://www.tipranks.com/news/dont-wait-for-the-dominoes-to-fall-says-top-investor-about-palantir-stock)
* [Goldman Sachs Bangs the Drum on Alphabet Stock](https://www.tipranks.com/news/goldman-sachs-bangs-the-drum-on-alphabet-stock)
* [‘Not the Time to Jump In,’ Says Needham About Tesla Stock](https://www.tipranks.com/news/not-the-time-to-jump-in-says-needham-about-tesla-stock)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/neurizon-therapeutics-announces-half-year-update-webinar)
